Literature DB >> 24671885

The role of digitalis pharmacokinetics in converting atrial fibrillation and flutter to regular sinus rhythm.

Roger W Jelliffe1.   

Abstract

This report examined the role of digitalis pharmacokinetics in helping to guide therapy with digitalis glycosides with regard to converting atrial fibrillation (AF) or flutter to regular sinus rhythm (RSR). Pharmacokinetic models of digitoxin and digoxin, containing a peripheral non-serum effect compartment, were used to analyze outcomes in a non-systematic literature review of five clinical studies, using the computed concentrations of digitoxin and digoxin in the effect compartment of these models in an analysis of their outcomes. Four cases treated by the author were similarly examined. Three literature studies showed results no different from placebo. Dosage regimens achieved ≤11 ng/g in the model's peripheral compartment. However, two other studies achieved significant conversion to RSR. Their peripheral concentrations were 9-14 ng/g. In the four patients treated by the author, three converted using classical clinical titration with incremental doses, plus therapeutic drug monitoring and pharmacokinetic guidance from the models for maintenance dosage. They converted at peripheral concentrations of 9-18 ng/g, similar to the two studies above. No toxicity was seen. Successful maintenance was achieved, using the models and their pharmacokinetic guidance, by giving somewhat larger than average recommended dosage regimens in order to maintain peripheral concentrations present at conversion. The fourth patient did not convert, but only reached peripheral concentrations of 6-7 ng/g, similar to the studies in which conversion was no better than placebo. Pharmacokinetic analysis and guidance play a highly significant role in converting AF to RSR. To the author's knowledge, this has not been specifically described before. In my experience, conversion of AF or flutter to RSR does not occur until peripheral concentrations of 9-18 ng/g are reached. Results in the four cases correlated well with the literature findings. More work is needed to further evaluate these provocative findings.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24671885      PMCID: PMC4286389          DOI: 10.1007/s40262-014-0141-6

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  26 in total

1.  Achieving target goals most precisely using nonparametric compartmental models and "multiple model" design of dosage regimens.

Authors:  R Jelliffe; D Bayard; M Milman; M Van Guilder; A Schumitzky
Journal:  Ther Drug Monit       Date:  2000-06       Impact factor: 3.681

2.  Creating discrete joint densities from continuous ones: the moment matching-maximum entropy approach.

Authors:  M Milman; F Jiang; R Jelliffe
Journal:  Comput Biol Med       Date:  2001-05       Impact factor: 4.589

3.  Studies on the renal excretion of radioactive digitoxin in human subjects with cardiac failure.

Authors:  G T OKITA; F E KELSEY; P J TALSO; L B SMITH; E M K GEILING
Journal:  Circulation       Date:  1953-02       Impact factor: 29.690

Review 4.  Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy.

Authors:  Roger W Jelliffe
Journal:  Ther Drug Monit       Date:  2012-08       Impact factor: 3.681

Review 5.  Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals.

Authors:  R W Jelliffe; A Schumitzky; D Bayard; M Milman; M Van Guilder; X Wang; F Jiang; X Barbaut; P Maire
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

6.  Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo.

Authors:  L Jordaens; J Trouerbach; P Calle; R Tavernier; E Derycke; P Vertongen; B Bergez; Y Vandekerckhove
Journal:  Eur Heart J       Date:  1997-04       Impact factor: 29.983

7.  Intravenous digoxin in acute atrial fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group.

Authors: 
Journal:  Eur Heart J       Date:  1997-04       Impact factor: 29.983

8.  Estimation of creatinine clearance in patients with unstable renal function, without a urine specimen.

Authors:  Roger Jelliffe
Journal:  Am J Nephrol       Date:  2002 Jul-Aug       Impact factor: 3.754

9.  A two-compartment population pharmacokinetic-pharmacodynamic model of digoxin in adults, with implications for dosage.

Authors:  Roger W Jelliffe; Mark Milman; Alan Schumitzky; David Bayard; Michael Van Guilder
Journal:  Ther Drug Monit       Date:  2014-06       Impact factor: 3.681

10.  Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial.

Authors:  Björn Hornestam; Markus Jerling; Mats O Karlsson; Peter Held
Journal:  Eur J Clin Pharmacol       Date:  2003-02-19       Impact factor: 2.953

View more
  4 in total

1.  Comment on: "The Role of Digitalis Pharmacokinetics in Converting Atrial Fibrillation and Flutter to Sinus Rhythm".

Authors:  Henrique Horta Veloso
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

2.  Author's reply to Veloso HH Comment on "The Role of Digitalis Pharmacokinetics in Converting Atrial Fibrillation and Flutter to Sinus Rhythm".

Authors:  Roger W Jelliffe
Journal:  Clin Pharmacokinet       Date:  2016-05       Impact factor: 6.447

3.  Expert Discussion of the Role of Rate Constant Versus Clearance Approaches to Define Drug Pharmacokinetics: Theoretical and Clinical Considerations.

Authors:  Marilyn N Martinez; Roger W Jelliffe; Johannes H Proost
Journal:  AAPS J       Date:  2020-01-06       Impact factor: 4.009

Review 4.  Research Progress in Pharmacological Activities and Applications of Cardiotonic Steroids.

Authors:  Junwei Ren; Xinyuan Gao; Xi Guo; Ning Wang; Xin Wang
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.